Antiviral treatment for COVID-19: the evidence supporting remdesivir
Charlotte Richardson, Sanjay Bhagani and Gabriele Pollara
DOI: https://doi.org/10.7861/clinmed.2020-0524
Clin Med November 2020 Charlotte Richardson
ARoyal Free London NHS Foundation Trust
Roles: specialist registrar in infectious diseases
Sanjay Bhagani
BRoyal Free London NHS Foundation Trust, and honorary senior lecturer, University College London
Roles: consultant physician in infectious diseases
Gabriele Pollara
CRoyal Free London NHS Foundation Trust, and Wellcome Trust postdoctoral clinical research fellow and NIHR clinical lecturer, University College London
Roles: specialist registrar in infectious diseases

Article Figures & Data
Tables
- Box 1.
NHS interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)13
Eligibility criteria (in accordance with the product licence): Hospitalised with COVID-19
With pneumonia requiring supplemental oxygen
Adults, and adolescents ≥12 years of age and ≥40 kg
eGFR ≥30 ml/min
Alanine aminotransferase (ALT) below 5 times the upper limit of normal at baseline
Article Tools
Antiviral treatment for COVID-19: the evidence supporting remdesivir
Charlotte Richardson, Sanjay Bhagani, Gabriele Pollara
Clinical Medicine Nov 2020, 20 (6) e215-e217; DOI: 10.7861/clinmed.2020-0524
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.